Hypercalcemia of Malignancy

Mechanisms, clinical recognition, and urgency-stratified management of the most common life-threatening metabolic complication of cancer

Key Points

• Hypercalcemia of malignancy (HCM) occurs in 20–30% of cancer patients over the course of disease and is caused primarily by PTHrP secretion (80% of cases), osteolytic bone destruction, or ectopic calcitriol production.
• Corrected calcium >12 mg/dL is symptomatic in most patients; levels >14 mg/dL constitute a medical emergency with risk of cardiac arrhythmia, coma, and death.
• IV fluid resuscitation (normal saline) is the essential first step — corrects dehydration, promotes renal calcium excretion, and must precede or accompany all other interventions.
• Zoledronic acid 4 mg IV is the most potent bisphosphonate for HCM; it normalizes calcium in 70–90% of patients within 4–7 days (ASCO evidence Grade 1A).
• Denosumab 120 mg SC is the preferred treatment for HCM refractory to bisphosphonates or in patients with severe renal impairment (eGFR <30 mL/min), where bisphosphonates are contraindicated.
• HCM indicates advanced or refractory malignancy in most cases — the median survival without disease control is 1–3 months; goals-of-care discussions are an essential part of management.

Pathophysiology and Mechanisms

Hypercalcemia of malignancy (HCM) is the most common life-threatening metabolic complication of cancer, affecting approximately 20–30% of patients at some point in their disease course. Understanding the mechanism guides treatment selection — not all HCM is managed identically. **1. PTHrP-Mediated Hypercalcemia (Humoral Hypercalcemia of Malignancy — HHM) — ~80% of cases:** Parathyroid hormone-related protein (PTHrP) is produced by the tumor and acts on the same PTH/PTHrP receptor as native PTH. It stimulates: - Osteoclast activation → increased bone resorption and calcium release from bone -…

Clinical Presentation — "Bones, Stones, Groans, and Psychic Overtones"

The clinical manifestations of hypercalcemia span all major organ systems and correlate with both the absolute calcium level and the rapidity of onset. The classic mnemonic — bones, stones, groans, and psychic overtones — captures the multisystem nature of hypercalcemia. **Neurological / Neuromuscular ("Psychic Overtones"):** The most common early symptoms. Even mild hypercalcemia (Ca 10.5–12 mg/dL) causes: - Fatigue, weakness, and easy fatigability - Cognitive impairment: difficulty concentrating, confusion, memory difficulties - Depression, anxiety, and personality changes - Hyporeflexia…

Urgency Stratification and Initial Management

The urgency of intervention is determined by the corrected calcium level AND the presence of symptoms. Do not treat based on the number alone — a patient with mild symptoms at Ca 12 mg/dL may be watched more conservatively, while a patient with Ca 11.5 mg/dL who is confused and in AKI requires urgent intervention. **Mild HCM (corrected Ca 10.5–12 mg/dL, minimal or no symptoms):** - Oral hydration (encourage 2–3 L/day of fluids) - Treat underlying malignancy if possible - Avoid calcium-containing supplements, vitamin D supplementation, thiazide diuretics (reduce renal calcium excretion), and…

Bisphosphonates, Denosumab, and Specific Treatments

**Bisphosphonates — First-Line for Moderate/Severe HCM:** Bisphosphonates inhibit osteoclast function and induce osteoclast apoptosis, reducing bone resorption and calcium release from bone. They are the established first-line treatment for PTHrP-mediated and osteolytic HCM. *Zoledronic acid* (Zometa) 4 mg IV over 15–30 minutes: - Most potent IV bisphosphonate; normalizes calcium in 70–90% of patients within 4–7 days - Duration of effect: 2–4 weeks (longer than pamidronate) - Superiority vs. pamidronate: demonstrated in randomized Phase 3 trials (Major P et al., J Clin Oncol 2001) - **Renal…

Prognosis, Goals of Care, and Recurrence Prevention

**Prognosis:** The development of HCM is a harbinger of advanced, often treatment-refractory malignancy. Historically, the median survival after a first episode of HCM was 30–90 days when the underlying malignancy was not controllable. Modern targeted therapies have extended this in specific tumor types, but HCM generally signals that the cancer is progressing despite treatment. Prognostic factors associated with better survival after HCM: - Disease amenable to effective systemic treatment (e.g., multiple myeloma responding to novel agents, breast cancer with active hormonal therapy options)…